The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
 
Rachel Kim
No Relationships to Disclose
 
Alex Makhnin
No Relationships to Disclose
 
Linda Su Hyun Ahn
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Sara A. Hayes
No Relationships to Disclose
 
Robert J. Young
Consulting or Advisory Role - Agios; ICON Clinical Research; NordicNeuroLab; Puma Biotechnology
Research Funding - Agios (Inst)
 
Gregory J. Riely
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Memorial Sloan-Kettering Cancer Center